


11TH SINGAPORE SLEEP, ALLERGY & RHINOLOGY VIRTUAL CONFERENCE

13 – 14 NOVEMBER 2021




11TH SINGAPORE SLEEP, ALLERGY & RHINOLOGY CONFERENCE DAY 1: SATURDAY, 13 NOVEMBER 2021

0730 – 0745	WELCOME	
0745 – 0905	CHRONIC RHINOSINUSITIS	
Moderators	Dr David Chin / Prof Teti Madiadipoera	
0745 – 0805	Approach & Management of Recurrent Nasal Polyposis Prof Martin J Citardi, University of Texas Medical School at Houston, Texas, USA	MEDTRONIC VIRTUAL HOSPITALITY SUITE
0805 – 0825	Using Biomarkers to Inform Management in Chronic Rhinosinusitis Dr Noam Cohen, University of Pennsylvania, USA	
0825 – 0845	Management of Sinonasal Inflammatory Disease with Biologics Prof Matthew Ryan, University of Texas Southwestern Medical Center, Dallas, Texas, USA	
0845 – 0905	Panel Discussion	
0905 – 0915	Break	
0915 – 1035	GEMS FOR IMPROVING OUTCOMES IN SINONASAL SURGERY	
Moderators	Dr Kornkiat Snidvongs / Prof Maung Maung Khaing	
0915 – 0935	Improving Outcomes in Frontal Sinus Drillout with Mucosal Flaps – How I Do It Dr Kazuhiro Omura, The Jikei University School of Medicine, Tokyo, Japan	MEDTRONIC VIRTUAL HOSPITALITY SUITE
0935 – 0955	Septal Perforation Repair – How I Do It Prof Raymond Sacks, Faculty of Medicine and Health Sciences, Macquarie University, Australia	
0955 – 1015	Nasal Valve Dysfunction Prof Richard J Harvey, University of New South Wales (Conjoint A/Prof) and Macquarie University (Clinical Prof), Australia	
1015 – 1035	Panel Discussion	
1035 – 1045	Break	
1045 – 1205	ADVANCES IN RHINOLOGY PRACTICE	
Moderators	Dr Retno S Wardani / A/Prof Pongsakorn Tantilipikorn	
1045 – 1105	Cryotherapy for Allergic and Non-Allergic Rhinitis Prof Martin J Citardi, University of Texas Medical School at Houston, Texas, USA	MEDTRONIC VIRTUAL HOSPITALITY SUITE
1105 – 1125	Ergonomics of Endoscopic Sinus and Skull Base Surgery. How to Set Yourself Up for Musculoskeletal Success and Longevity Dr Raewyn Campbell, Mater Hospital, Sydney, Australia	
1125 – 1145	Role of The Nasal Epithelium in SARS-Cov-2 Infection Dr Noam Cohen, University of Pennsylvania, USA	
1145 – 1205	Panel Discussion	
1205 – 1215	Break	
1215 – 1315	LUNCH SYMPOSIUM (SPONSORED BY A. MENARINI SINGAPORE PTE LTD)	
1315 – 1435	ALLERGIC RHINITIS	
Moderators	Prof Wang De Yun / Dr Budi Sutikno	
1315 – 1335	Approach & Management of Difficult Allergic Rhinitis Prof Joaquim Mullol, Hospital Clínic - IDIBAPS, Barcelona, Catalonia, Spain	MEDTRONIC VIRTUAL HOSPITALITY SUITE
1335 – 1355	Loss of Smell as Clinical Biomarker of Severity in AR and Asthma Prof Joaquim Mullol, Hospital Clínic - IDIBAPS, Barcelona, Catalonia, Spain	
1355 – 1415	Is There a Role for Biologics in Severe Allergic Rhinitis Prof Philippe Gevaert, Ghent University, Belgium	
1415 – 1435	Panel Discussion	
1435 – 1445	Break	
1445 – 1605	ENDOSCOPIC SINUS SURGERY I	
Moderators	Dr PK Purushothaman / Dr Rusdian Utama Roeslani	
1445 – 1505	Frontal Sinus Surgery – My Approach Prof Philippe Gevaert, Ghent University, Belgium	MEDTRONIC VIRTUAL HOSPITALITY SUITE
1505 – 1525	How I Do It: Decision Making and Techniques in Frontal Sinus Drillout and Medial Maxillectomy Dr Raewyn Campbell, Mater Hospital, Sydney, Australia	
1525 – 1545	The Limits of Endoscopic Frontal Sinus Surgery Prof Darlene Lubbe, University of Cape Town, Cape Town, South Africa	
1545 – 1605	Panel Discussion	
1605 – 1615	Break	
1615 – 1735	ENDOSCOPIC SINUS SURGERY II	
Moderators	Dr Sroy Adollar / Prof Phone Myint Tun / Prof Dr Baharudin Abdullah	
1615 – 1635	Maxillary Sinus Surgery – My Approach Prof Raymond Sacks, Faculty of Medicine and Health Sciences, Macquarie University, Australia	MEDTRONIC VIRTUAL HOSPITALITY SUITE
1635 – 1655	Challenging Cases involving The Maxillary Sinus – How I Do It Prof Darlene Lubbe, University of Cape Town, Cape Town, South Africa	
1655 – 1715	Novel Approaches for Endoscopic Excision of Sinonasal Inverted Papilloma Dr Kazuhiro Omura, The Jikei University School of Medicine, Tokyo, Japan	
1715 – 1735	Panel Discussion	
1735	End of Day 1	

11TH SINGAPORE SLEEP, ALLERGY & RHINOLOGY VIRTUAL CONFERENCE

13 – 14 NOVEMBER 2021



11TH SINGAPORE SLEEP, ALLERGY & RHINOLOGY CONFERENCE DAY 2: SUNDAY, 14 NOVEMBER 2021

0800 – 0920	ENDOSCOPIC SKULL BASE I
Moderators	Dr Pornthep Kasemsiri / A/Prof Dharambir S Sethi / Dr Soma Subramaniam
0800 – 0820	Endoscopic Endonasal Management of Tumours with Carotid Involvement Prof Arturo Solares, Emory University, Atlanta, GA, USA
0820 – 0840	Reconstruction for ESBS: Beyond the Nasoseptal Flap Dr Eric W. Wang, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
0840 – 0900	ICA Injury During EEA: Perioperative Management Prof Ricardo L Carrau, The Ohio State University Wexner Medical Center & The James Cancer Center, USA
0900 – 0920	Panel Discussion
0920 – 0930	Break
0930 – 1100	LIVE SURGERY I
Moderators	Prof Dr Tang Ing Ping / Dr Eric W. Wang
0930 – 1100	Live Commentary & Discussion Dr T N Janakiram, Royal Pearl Hospital, Trichy, Tamil Nadu, India
1100 – 1200	ENDOSCOPIC SKULL BASE II
Moderators	A/Prof Luan Tran / Dr Raewyn Campbell
1100 – 1120	How I Do It: Routine Pituitary Surgery Prof Richard J Harvey, University of New South Wales (Conjoint A/Prof) and Macquarie University (Clinical Prof), Australia
1120 – 1140	Endoscopic Transorbital Approaches to the Skull Base Prof Darlene Lubbe, University of Cape Town, Cape Town, South Africa
1140 – 1200	Panel Discussion
1200 – 1300	LUNCH SYMPOSIUM (SPONSORED BY KARL STORZ ENDOSCOPY ASIA MARKETING PTE LTD)
Moderator	Dr Leong Jern-Lin
1300 – 1430	LIVE SURGERY II
Moderators	Dr Budi Sutikno / Prof Richard J Harvey / Prof Darlene Lubbe
1300 – 1430	Live Commentary & Discussion Dr Satish Jain, Jain ENT Hospital, NIMS University & Narayana Multispecialty Hospital, Jaipur, India
1430	End of Day 2



DEXILANT[®] : THE FIRST PPI WITH DUAL DELAYED RELEASE TECHNOLOGY^{1,7}

HEARTBURN RELIEF UP TO 24-HOURS²

 **DEXILANT[®]** has a unique mechanism of action delivering two drug releases^{3,4}



DEXILANT[®] can be administered independent of food intake and mealtimes^{5,6}

DEXILANT[®] provides extended duration of acid control to help control nocturnal symptoms and achieve up to 24-hour heartburn relief²

REFERENCES

1. Vakily M, Zhang W, Wu J, Atkinson SN, Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. *Curr Med Res Opin.* 2009;25(3):627-38.
2. Metz DC, Howden CW, Perez MC, Larsen L, O'Neil J, Atkinson SN. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. *Aliment Pharmacol Ther.* 2009;29(7):742-54. 3. Wittbrodt ET, et al. *Clin Exp Gastroenterol* 2009;2:117-28. 4. Kukulka, M et al. *Clin Exp Gastroenterol* 2011;4:213-20 5. Lee RD, et al. *Aliment Pharmacol Ther* 2010;31:1001-11. 6. Frye JW, Peura DA, *Ther Clin Risk Manag* 2015;11:1649-56. 7. Goh KL, et al. *J Neurogastroenterol Motil.* 2016 Jul 30;22(3):355-66.

DEXILANT[®] 30mg & 60mg capsules

Abbreviated Singapore Prescribing Information

Composition: DEXILANT[®] 30mg delayed-release capsule contains 30mg of dexlansoprazole, DEXILANT[®] 60mg delayed-release capsule contains 60mg of dexlansoprazole. **Indication:** Adults and in adolescents 12 to 17 years of age for the following: **Healing of Erosive Esophagitis (EE):** Healing of all grades of EE for up to 8 weeks, **Maintenance of Healed EE:** Maintain healing of EE and relief of heartburn for up to 6 months, **Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD):** Treatment of heartburn and acid regurgitation associated with symptomatic non-erosive GERD for 4 weeks. **Dosage and Administration:** Taken without regard to food or timing of food. Can be swallowed whole or open capsule and sprinkle granules on one tablespoon of applesauce and swallow immediately. Granules should not be chewed. Can be administered with water in an oral syringe or via a nasogastric tube (≥16 French). For adults and in adolescents 12 to 17 years of age: **Healing EE:** 60mg once daily for up to 8 weeks, **Maintenance of Healed EE and relief of heartburn:** 30mg once daily for up to 6 months, **Symptomatic Non-erosive GERD:** 30mg once daily for 4 weeks. **Contraindications:** Hypersensitivity to any component of the formulation. Hypersensitivity and anaphylaxis have been reported. **Special Precautions:** Symptomatic response with DEXILANT[®] does not preclude the presence of gastric malignancy. PPI therapy may be associated with an increased risk of CDAD, AIN, CLE and SLE. Risk of Bone Fracture and Hypomagnesemia (and which may lead to hypocalcemia and/or hypokalemia). Concomitant use w/ Methotrexate and HIV protease inhibitors. Influence on Vitamin B-12 Absorption. Interference with Chromogranin A (CgA) level. Pregnancy and lactation. **Undesirable Effects: Common:** Diarrhoea, Abdominal Pain, Nausea, Upper Respiratory Tract Infection, Vomiting and Flatulence. **Drug-Drug Interactions:** May affect absorption of drugs which are pH dependent (e.g. ketoconazole). Reduces bioavailability of atazanavir and nelfinavir. Warfarin (monitor prothrombin time/INR). May increase whole blood levels of tacrolimus. May elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate. Drugs that Inhibit or Induce CYP2C19.

Refer to full Singapore prescribing information for further details; full prescribing information available upon request. C-APROM/SG/DEXI/0007 MARCH 2021



For more information, please contact:
TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.
8 Marina Boulevard, #05-02, Marina Bay Financial Centre Tower 1,
Singapore 018981

Tel: +65 6812 3900 | www.takeda.com

For Healthcare Professionals only.